RE:RE:ONCY presentation @ August 12th Cannacord fireside chat I've often considered that it would be worthwhile for ONCY to submit their phase III CTA proposing a surrogate primary end point - other than OS. If you can demonstrate that OS is almost guaranteed if you prove stimualtion of an appropriate immune response, then you could shorten the time to submission by 12-18 months.
But, Matt has never made any mention of this. If investors thought there was a chance for a faster route of approval, then certainly it would be worth mentioning. But no... we get nothing but more comments of 'interesting' results.
No matter,. the pps will bottom next month, and by year end, we'll all be temporarily content.
but until the phase III partner is announced, any end oif year rise, will be met with an equal drop. I'm under no illusions here.
GLTA